Protocol for the MPTP mouse model of Parkinson's disease

[1]  Michael Ruse,et al.  Mechanisms and Models , 2007 .

[2]  Jeffrey H Kordower,et al.  Proteasome inhibition and Parkinson's disease modeling , 2006, Annals of neurology.

[3]  Anthony E. Lang,et al.  Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics , 2005 .

[4]  H. Ischiropoulos.  Faculty Opinions recommendation of Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005 .

[5]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Przedborski,et al.  Neurodegenerative Diseases: Toxic animal models , 2005 .

[7]  M. Vila,et al.  D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. , 2003, The Journal of clinical investigation.

[8]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[9]  S. Totterdell,et al.  Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson’s disease , 2002, Brain Research.

[10]  Elan D. Louis,et al.  Merritt's Neurology , 2001 .

[11]  G. Petzinger,et al.  The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.

[12]  S. Korsmeyer,et al.  Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[14]  P. Sonsalla,et al.  Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. , 2000, The Journal of pharmacology and experimental therapeutics.

[15]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[16]  J. O'Callaghan,et al.  The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity , 1998, Annals of the New York Academy of Sciences.

[17]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[18]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[19]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[20]  P. Sonsalla,et al.  Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. , 1994, The Journal of pharmacology and experimental therapeutics.

[21]  P. Sonsalla,et al.  Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. , 1994, The Journal of pharmacology and experimental therapeutics.

[22]  R. Edwards,et al.  Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  P. Sonsalla,et al.  Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. , 1991, The Journal of pharmacology and experimental therapeutics.

[25]  P. Sonsalla,et al.  Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. , 1989, Molecular and chemical neuropathology.

[26]  S. Markey,et al.  Recommended safe practices for using the neurotoxin MPTP in animal experiments. , 1988, Laboratory animal science.

[27]  K. Chiba,et al.  Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. , 1988, The Journal of pharmacology and experimental therapeutics.

[28]  N. Castagnoli,et al.  Cation-exchange high-performance liquid chromatography assay for the nigrostriatal toxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B generated metabolites in brain tissues. , 1987, Journal of chromatography.

[29]  P. Sonsalla,et al.  The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. , 1986, European journal of pharmacology.

[30]  R. Ramsay,et al.  Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.

[31]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[33]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[34]  John A. Kiernan,et al.  Histological and Histochemical Methods: Theory and Practice , 1981 .

[35]  M. Youdim.  Assay and Purification of Brain Monoamine Oxidase , 1975 .

[36]  Y. Agid,et al.  Injection of 6-hydroxydopamine in the substantia nigra of the rat. I. Morphological study. , 1973, Brain research.